Beurs gesloten -
Japan Exchange
08:00:00 16-05-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
565
JPY
|
-20,98%
|
|
-21,42%
|
-44,33%
|
Fiscaal tijdperk: Maart |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
8.866
|
3.518
|
7.340
|
6.937
|
6.560
|
Bedrijfswaarde
1 |
5.370
|
1.580
|
5.252
|
5.669
|
5.716
|
K/w-verhouding
|
-11,9
x
|
-2,24
x
|
-7,4
x
|
-7,17
x
|
-4,39
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
-
|
35,2
x
|
24,5
x
|
23,1
x
|
-
|
Bedrijfswaarde/omzet
|
-
|
15,8
x
|
17,5
x
|
18,9
x
|
-
|
Bedrijfswaarde/EBITDA
|
-9.086.156
x
|
-1.023.360
x
|
-6.178.665
x
|
-5.905.091
x
|
-4.350.444
x
|
Bedrijfswaarde/FCF
|
-16.993.413
x
|
-1.468.976
x
|
-13.015.776
x
|
-9.848.229
x
|
-7.084.721
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
2,53
x
|
1,71
x
|
3,27
x
|
5,63
x
|
8,2
x
|
Aantal aandelen (in duizenden)
|
4.370
|
4.505
|
5.300
|
5.419
|
6.369
|
Referentieprijs
2 |
2.029
|
781,0
|
1.385
|
1.280
|
1.030
|
Datum van publicatie
|
24/06/19
|
29/06/20
|
30/06/21
|
30/06/22
|
26/06/23
|
Fiscaal tijdperk: Maart |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
150
|
-
|
100
|
300
|
300
|
-
|
EBITDA
|
-
|
-591
|
-1.544
|
-850
|
-960
|
-1.314
|
Bedrijfsresultaat (EBIT)
1 |
-243
|
-592
|
-1.545
|
-852
|
-961
|
-1.315
|
Operationele Marge
|
-162%
|
-
|
-1.545%
|
-284%
|
-320,33%
|
-
|
Resultaat voor belastingen (EBT)
1 |
-245
|
-671
|
-1.552
|
-859
|
-964
|
-1.325
|
Nettowinst (verlies)
1 |
-246
|
-673
|
-1.555
|
-862
|
-967
|
-1.328
|
Nettomarge
|
-164%
|
-
|
-1.555%
|
-287,33%
|
-322,33%
|
-
|
WPA
2 |
-92,09
|
-170,0
|
-348,1
|
-187,2
|
-178,5
|
-234,4
|
Free Cash Flow
|
-
|
-316
|
-1.076
|
-403,5
|
-575,6
|
-806,9
|
FCF-marge
|
-
|
-
|
-1.075,62%
|
-134,5%
|
-191,88%
|
-
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
5/09/18
|
24/06/19
|
29/06/20
|
30/06/21
|
30/06/22
|
26/06/23
|
Fiscaal tijdperk: Maart |
2020 S1
|
2021 S1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2024 Q1
|
2024 S1
|
2024 Q3
|
---|
Omzet
|
-
|
100
|
100
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Bedrijfsresultaat (EBIT)
1 |
-725
|
-463
|
-554
|
-278
|
-304
|
-611
|
-415
|
-275
|
-593
|
-356
|
Operationele Marge
|
-
|
-463%
|
-554%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Resultaat voor belastingen (EBT)
1 |
-729
|
-463
|
-555
|
-280
|
-307
|
-620
|
-415
|
-280
|
-599
|
-372
|
Nettowinst (verlies)
1 |
-731
|
-464
|
-557
|
-280
|
-308
|
-622
|
-416
|
-280
|
-600
|
-372
|
Nettomarge
|
-
|
-464%
|
-557%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
WPA
2 |
-165,2
|
-103,2
|
-103,0
|
-51,68
|
-56,96
|
-114,9
|
-75,30
|
-43,07
|
-91,92
|
-50,17
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
14/11/19
|
12/11/20
|
11/11/21
|
14/02/22
|
12/08/22
|
14/11/22
|
14/02/23
|
14/08/23
|
13/11/23
|
13/02/24
|
Fiscaal tijdperk: Maart |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
762
|
3.496
|
1.938
|
2.088
|
1.268
|
844
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-316
|
-1.076
|
-404
|
-576
|
-807
|
ROE (netto-inkomsten/eigen vermogen)
|
-30,9%
|
-31,1%
|
-55,9%
|
-41,7%
|
-58,4%
|
-131%
|
ROA (netto-inkomsten/totale activa)
|
-16,6%
|
-16,7%
|
-33,7%
|
-24,6%
|
-34,5%
|
-73,7%
|
Totale activa
1 |
1.484
|
4.030
|
4.613
|
3.499
|
2.805
|
1.802
|
Nettoactief per aandeel
2 |
308,0
|
803,0
|
456,0
|
424,0
|
227,0
|
126,0
|
Cashflow per aandeel
2 |
292,0
|
804,0
|
431,0
|
426,0
|
234,0
|
134,0
|
Capex
|
-
|
1
|
13
|
-
|
-
|
-
|
Capex/omzet
|
-
|
-
|
13%
|
-
|
-
|
-
|
Datum van publicatie
|
5/09/18
|
24/06/19
|
29/06/20
|
30/06/21
|
30/06/22
|
26/06/23
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| -44,33% | 38 mln. | | +35,01% | 709 mld. | | +29,31% | 595 mld. | | -2,60% | 367 mld. | | +20,83% | 334 mld. | | +5,69% | 289 mld. | | +14,66% | 239 mld. | | +9,37% | 211 mld. | | -3,68% | 203 mld. | | +10,77% | 171 mld. |
Farmaceutische producten - Andere
|